Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 20Recruiting 9Unknown 3Terminated 2Not yet recruiting 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Plasma cell 1

Conditions

Venous Thromboembolism 2Venous Thrombosis 1Pulmonary Embolism 1Multiple Myeloma 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × apixaban × Clear all
NCT05171049 2026-02-23

ASTER

Anthos Therapeutics, Inc.

Phase 3 Terminated
1,150 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT04106700 2021-02-15

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Instituto de Investigacion Sanitaria La Fe

Phase 2 Terminated
60 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡